Abstract
Aim: Congestion is a major determinant of outcomes in acute heart failure. Its assessment is complex, making sufficient decongestive therapy a challenge. Residual congestion is frequent at discharge, increasing the risk of re‐hospitalization and death. Mid‐regional pro‐adrenomedullin mirrors vascular integrity and may therefore be an objective marker to quantify congestion and to guide decongestive therapies in patients with acute heart failure.
Methods and results: Observational, prospective, single‐centre study in unselected patients presenting with acute heart failure. This study aimed to assess adrenomedullin's association with congestion and clinical outcomes: in‐hospital death, post‐discharge mortality and in‐hospital worsening heart failure according to RELAX‐AHF‐2 trial criteria. Pro‐adrenomedullin was quantified at baseline and at discharge. Congestion was assessed applying clinical scores. Cox and logistic regression models with adjustment for clinical features were fitted. N = 233, median age 77 years (IQR 67, 83), 148 male (63.5%). Median pro‐adrenomedullin 2.0 nmol/L (IQR 1.4, 2.9). Eight patients (3.5%) died in hospital and 100 (44.1%) experienced in‐hospital worsening heart failure. After discharge, 60 patients (36.6%) died over a median follow‐up of 1.92 years (95% CI: 1.76, 2.46). Pro‐adrenomedullin concentrations (logarithmized) were significantly associated with congestion, both at enrolment (β = 0.36 and 0.81 depending on score, each P < 0.05) and at discharge (β = 1.12, P < 0.001). Enrolment of pro‐adrenomedullin was associated with in‐hospital worsening heart failure [OR 4.23 (95% CI: 1.87, 9.58), P < 0.001], and pro‐adrenomedullin at discharge was associated with post‐discharge death [HR 3.93 (1.86, 8.67), P < 0.001].
Conclusion: Elevated pro‐adrenomedullin is associated with in‐hospital worsening heart failure and with death during follow‐up in patients with acute heart failure. Further research is needed to validate this finding and to explore the ability of pro‐adrenomedullin to guide decongestive treatment.
Methods and results: Observational, prospective, single‐centre study in unselected patients presenting with acute heart failure. This study aimed to assess adrenomedullin's association with congestion and clinical outcomes: in‐hospital death, post‐discharge mortality and in‐hospital worsening heart failure according to RELAX‐AHF‐2 trial criteria. Pro‐adrenomedullin was quantified at baseline and at discharge. Congestion was assessed applying clinical scores. Cox and logistic regression models with adjustment for clinical features were fitted. N = 233, median age 77 years (IQR 67, 83), 148 male (63.5%). Median pro‐adrenomedullin 2.0 nmol/L (IQR 1.4, 2.9). Eight patients (3.5%) died in hospital and 100 (44.1%) experienced in‐hospital worsening heart failure. After discharge, 60 patients (36.6%) died over a median follow‐up of 1.92 years (95% CI: 1.76, 2.46). Pro‐adrenomedullin concentrations (logarithmized) were significantly associated with congestion, both at enrolment (β = 0.36 and 0.81 depending on score, each P < 0.05) and at discharge (β = 1.12, P < 0.001). Enrolment of pro‐adrenomedullin was associated with in‐hospital worsening heart failure [OR 4.23 (95% CI: 1.87, 9.58), P < 0.001], and pro‐adrenomedullin at discharge was associated with post‐discharge death [HR 3.93 (1.86, 8.67), P < 0.001].
Conclusion: Elevated pro‐adrenomedullin is associated with in‐hospital worsening heart failure and with death during follow‐up in patients with acute heart failure. Further research is needed to validate this finding and to explore the ability of pro‐adrenomedullin to guide decongestive treatment.
| Original language | English |
|---|---|
| Journal | ESC heart failure |
| Early online date | 20 Aug 2024 |
| DOIs | |
| Publication status | E-pub ahead of print - 20 Aug 2024 |
Keywords
- Pro‐ADM
- Therapy guidance
- Acute heart failure
- Biomarker
- Congestion
- Adrenomedullin